Public procurement notice: Contract Notice
Published: 2017-05-20
Buyer: The Common Services Agency (more commonly known as NHS National Services Scotland) (‘the Authority’)
Country: UK
Region: UNITED KINGDOM
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 4818818 GBP
Submission deadline: 2017-06-21
Award criteria: The most economic tender

Technical requirements: The goods have been grouped together into 1 Lot, Full details are contained in section II.2 of this notice.
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
This framework agreement is for the supply of Bosentan 62.5 mg and 125 mg tablets to NHS Scotland. Product lines included will be grouped together into one lot as the requirement.
This will require supply of the medicine direct to hospitals and nominated home delivery supplier(s) as directed by the Authority.
The Authority intends awarding a single-supplier framework agreement for the requirement. Full details can be found within the ITT.
Option to extend by a further period of up to twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by approved by the MHRA for all tendered Medicines at the date of submission of the tender.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency (‘NPSA’) Guidelines on Packaging and Labelling on pack design.
(a) Confirmation of existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.
(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under Technical and Professional ability: Quality Assurance Schemes.
(c) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency (‘NPSA’) Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products.
The estimated values referred to in Section II.I.5 and II.2.6 cover the twenty-three (23) months contract duration and the twelve (12) month extension period of the framework agreement.
The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 8264. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343

Eligibility requirements: Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.

Award value: 4818818